We are live on ! Find out more
ASND icon

Ascendis Pharma A/S

264.92 USD
+1.40
0.53%
At close Updated Sep 14, 4:00 PM EDT
Pre-market
After hours
265.05
+0.13
0.05%
1 day
0.53%
5 days
0.57%
1 month
6.61%
3 months
18.64%
6 months
14.67%
Year to date
24.21%
1 year
36.12%
5 years
72.54%
10 years
1,202.46%
 

About: Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.

Employees: 1,189

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 22.7%
Neutral 77.3%
Negative 0%
Neutral
GlobeNewsWire
6 hours ago
Ascendis Announces Planned $400 Million Share Repurchase Program
COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company's ordinary shares (the Share Repurchase Program).
Ascendis Announces Planned $400 Million Share Repurchase Program
Neutral
GlobeNewsWire
6 hours ago
Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases
- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis- Ascendis to initiate multiple programs in metabolic and cardiovascular diseases, including obesity
Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases
Neutral
GlobeNewsWire
5 days ago
First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026
– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment
First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026
Neutral
GlobeNewsWire
6 days ago
Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
COPENHAGEN, Denmark, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time in New York, New York.
Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Neutral
GlobeNewsWire
7 days ago
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026
COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress of the European Society for Paediatric Endocrinology (ESPE) being held September 8-10, 2026, in Marseille, France. Updates will include a podium presentation of the first sentinel cohort data from the pivotal reACHin Trial of TransCon CNP (navepegritide) in infants with achondroplasia aged 0 to
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026
Neutral
Benzinga
14 days ago
Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday.
Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday
Positive
Benzinga
14 days ago
Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes
On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reached a binding settlement with Ascendis Pharma A/S (NASDAQ:ASND)to resolve all global patent disputes regarding the medication Yuviwel.
Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes
Neutral
GlobeNewsWire
14 days ago
Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)
COPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with BioMarin Pharmaceutical Inc. (“BioMarin”) related to the sale of YUVIWEL® and navepegritide-related products. The binding term sheet provides the terms and conditions upon which the companies agree to resolve all litigation and disputes between the companies.
Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)
Positive
Benzinga
18 days ago
This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Neutral
GlobeNewsWire
20 days ago
Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026
COPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its participation at ISDS 2026, the annual meeting of the International Skeletal Dysplasia Society being held in Toronto, Canada, from August 26-29, 2026, will include an oral presentation of Week 104 data from its pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. The presentation will be given by Carlos Bacino, M.D., FACMG, Professor of Molecular and Human Genetics, Baylor College of Medicine and Texas Children's Hospital.
Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026
Price charts implemented using Lightweight Charts™